{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:12:10Z","timestamp":1790820730412,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.ejca.2006.10.014","type":"journal-article","created":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T10:12:23Z","timestamp":1166609543000},"page":"258-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":316,"title":["EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update"],"prefix":"10.1016","volume":"43","author":[{"given":"C.","family":"Bokemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Courdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Foubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2006.10.014_bib1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.ejca.2004.07.015","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer","volume":"40","author":"Bokemeyer","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2006.10.014_bib3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/ki.1996.487","article-title":"A randomised controlled study of iron supplementation in patients treated with erythropoietin","volume":"50","author":"MacDougall","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2006.10.014_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropeietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.3696.3696","article-title":"Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial","volume":"104","author":"Henry","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib6","doi-asserted-by":"crossref","first-page":"175a","DOI":"10.1182\/blood.V106.11.588.588","article-title":"Prospective targeted epoetin beta therapy for chemotherapy-associated anaemia achieves high response rates","volume":"106","author":"Agrawal","year":"2005","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.ejca.2006.10.014_bib7","first-page":"S187","article-title":"Novel hematologic markers for predicting response to r-HuEPO in anemic patients with multiple myeloma and lymphoma","volume":"90","author":"Katodritou","year":"2005","journal-title":"Hematol J"},{"key":"10.1016\/j.ejca.2006.10.014_bib8","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671\u2013679.","DOI":"10.1200\/JCO.1996.14.2.671"},{"key":"10.1016\/j.ejca.2006.10.014_bib9","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejca.2005.01.021","article-title":"Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa","volume":"41","author":"Glaspy","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11954","article-title":"A randomised controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies","volume":"100","author":"Hesketh","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib11","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"12","author":"Chang","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib12","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2005.03.024","article-title":"Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomized controlled trial","volume":"41","author":"Savonije","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib13","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","article-title":"Phase III randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/jco.2005.23.16_suppl.613","article-title":"Epoetin-alpha reduces red blood cell transfusions in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide","volume":"23","author":"Michael","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200507000-00004","article-title":"Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience","volume":"16","author":"Bartsch","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2006.10.014_bib16","first-page":"108","article-title":"The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients","volume":"14","author":"Heras","year":"2005","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.ejca.2006.10.014_bib17","first-page":"374","article-title":"Once-weekly epoetin beta improves hemoglobin and quality of life in anemic cancer patients receiving chemotherapy","volume":"3","author":"Katsumata","year":"2005","journal-title":"Eur J Cancer Suppl"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib18","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1200\/jco.2005.23.16_suppl.6703","article-title":"Epoetin alfa (EPO) vs standard of care (SOC) decreases number of PRBC transfusions (tx) in patients (pts) receiving hyper-CVAD for acute lymphocytic leukemia (ALL), lymphoblastic lymphoma (LL), and Burkitt\u2019s lymphoma (BL)","volume":"23","author":"Mattiuzzi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib19","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/cncr.20569","article-title":"Epoetin alfa improves quality of life in patients with cancer: results of a metaanalysis","volume":"101","author":"Jones","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2005.02.7276","article-title":"Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer","volume":"24","author":"Steensma","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib21","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","article-title":"Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from 4 randomized, double-blind placebo-controlled trials","volume":"23","author":"Hedenus","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2006.10.014_bib23","first-page":"253","article-title":"Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline","volume":"12","author":"Vansteenkiste","year":"2004","journal-title":"Support Care Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib24","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1200\/jco.2005.23.16_suppl.5102","article-title":"Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy","volume":"23","author":"Reed","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ejca.2006.10.014_bib25","first-page":"841P","article-title":"Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies","volume":"15","author":"Aapro","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib26","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/jco.2004.22.90140.5132","article-title":"Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer","volume":"22","author":"Marinaccio","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","article-title":"Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy","volume":"5","author":"O\u2019Shaughnessy","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djj053","article-title":"Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"98","author":"Canon","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2006.10.014_bib29","doi-asserted-by":"crossref","first-page":"A3556","DOI":"10.1182\/blood.V106.11.3556.3556","article-title":"Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia","volume":"106","author":"Taylor","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib30","first-page":"3063","article-title":"Early and sustained improvement in health-related quality of life (HRQOL) was observed with frontloaded darbepoetin alfa compared to conventional therapy","volume":"22","author":"Glaspy","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3770.3770","article-title":"Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: Final results","volume":"106","author":"Gregory","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3555.3555","article-title":"Maintenance dosing with epoetin alfa every three weeks (q3w) in anemic patients with cancer receiving chemotherapy every three weeks: Final results","volume":"106","author":"Montoya","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib33","doi-asserted-by":"crossref","first-page":"A4228","DOI":"10.1182\/blood.V104.11.4228.4228","article-title":"Safety and efficacy of epoetin alfa initiated at 80,000 U once weekly in anemic cancer patients receiving chemotherapy","volume":"104","author":"Waltzman","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib34","article-title":"Early treatment with epoetin alfa improves anemia, quality of life, and productivity in patients with hematologic malignancies and mild anemia during chemotherapy","volume":"102","author":"Straus","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/cncr.11616","article-title":"Once-weekly dosing of epoetin-\u03b1 increases haemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy","volume":"98","author":"Shasha","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib36","first-page":"761s","article-title":"Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia","volume":"23","author":"Boccia","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.ejca.2006.10.014_bib37","first-page":"S187","article-title":"Efficacy and safety of epoetin beta (Neorecormon\u00ae) 30 000 iu once weekly in anaemic patients with non-myeloid malignancies receiving chemotherapy","volume":"90","author":"Salles","year":"2005","journal-title":"Hematol J"},{"key":"10.1016\/j.ejca.2006.10.014_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/030089160409000406","article-title":"Comparison of clinical outcomes of different erythropoietin usage strategies","volume":"90","author":"Arslan","year":"2004","journal-title":"Tumori"},{"issue":"suppl 14","key":"10.1016\/j.ejca.2006.10.014_bib39","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/jco.2004.22.90140.9586","article-title":"Corrected area under serum hemoglobin curve (Hb c-AUC) as a predictor of maximal hemoglobin response after erythropoietin (rHuEpo) treatment in chemotherapy induced anemia patients","volume":"22","author":"Banu","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 14","key":"10.1016\/j.ejca.2006.10.014_bib40","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1200\/jco.2004.22.90140.8245","article-title":"Reticulocytes can represent an early indicator of the erythropoietic response to darbepoetin alfa in the anemia by chemotherapy","volume":"22","author":"Bindi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib41","first-page":"A4368","article-title":"Epoetin alfa improves hemoglobin and quality of life in anemic geriatric cancer patients \u2a7e60 years receiving chemotherapy","volume":"102","author":"Demetri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.9-6-696","article-title":"A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer","volume":"9","author":"Schwartzberg","year":"2004","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ejca.2006.10.014_bib43","first-page":"A3743","article-title":"An investigation into the impact of weight on the efficacy of darbepoetin alfa administered as a fixed dose of 200 mcg every 2 weeks (Q2W)","volume":"102","author":"Heatherington","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib44","first-page":"A1814","article-title":"An open-label, randomized study to develop a screening tool for functional capacity in anemic subjects with nonmyeloid malignancies receiving chemotherapy and darbepoetin alfa","volume":"102","author":"Vadhan-Raj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib45","first-page":"1037","article-title":"Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice","volume":"14","author":"Pujade-Lauraine","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2006.10.014_bib46","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S1359-6349(03)90970-0","article-title":"Early administration of hemoglobin-adapted doses of erythropoietin with intravenous iron for the prevention of chemotherapy-induced anemia","volume":"1","author":"Monnerat","year":"2003","journal-title":"Eur J Cancer Suppl"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib47","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1200\/jco.2005.23.16_suppl.8230","article-title":"Epoetin beta treatment to prevent anemia in solid tumor patients receiving platinum-based chemotherapy","volume":"23","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","article-title":"Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis","volume":"97","author":"Bohlius","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2006.10.014_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2005.0049","article-title":"Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia","volume":"3","author":"Campos","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2006.10.014_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib51","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/cncr.21042","article-title":"Epoetin-alpha during radiotherapy for stage III esophageal carcinoma","volume":"103","author":"Rades","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1359-6349(03)90953-0","article-title":"Final results of a randomized II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors","volume":"1","author":"Antonadou","year":"2003","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2006.10.014_bib53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1359-6349(05)81588-5","article-title":"A multicenter, open study evaluating the impact of darbepoetin alfa on anaemia and quality of life, in cancer patients undergoing radiotherapy","volume":"3","author":"Antonadou","year":"2005","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2006.10.014_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0360-3016(00)01526-1","article-title":"Hyperfractionated chemoradiation with carbogen breathing with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer","volume":"50","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2006.10.014_bib55","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2006.10.014_bib56","first-page":"1689","article-title":"Multicenter randomized phase II study of pacitaxel (1-hour infusion), flurouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advance head and neck cancer","volume":"9","author":"Rosen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.10.014_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2004.07.009","article-title":"Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study","volume":"95","author":"Lavey","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ejca.2006.10.014_bib58","first-page":"A477PD","article-title":"Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study","volume":"15","author":"Blohmer","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib59","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/jco.2005.23.16_suppl.5121","article-title":"Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy","volume":"23","author":"Strauss","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib60","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/ASO.2005.06.031","article-title":"Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study","volume":"12","author":"Christodoulakis","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib61","first-page":"129","article-title":"Administration of recombinant human erythropoietin in patients with gynecological cancer before radical surgery","volume":"32","author":"Dousias","year":"2005","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.ejca.2006.10.014_bib62","first-page":"S272","article-title":"Clinical evaluation of once weekly dosing of epoetin alpha in multiple myeloma patients: improvements in hemoglobin are similar to three-times-weekly dosing","volume":"5","author":"Alymara","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.ejca.2006.10.014_bib63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.10-9-743","article-title":"Management of cancer-related anemia in patients with breast or gynecolgic cancer: new insights based on results from the European Cancer Anemia Survey","volume":"10","author":"Barrett-Lee","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2006.10.014_bib64","doi-asserted-by":"crossref","first-page":"A4223","DOI":"10.1182\/blood.V104.11.4223.4223","article-title":"Epoetin alfa 40,000 U QW increases Hb and is safe in anemic patients with cancer not receiving chemotherapy or radiation therapy","volume":"104","author":"Shasha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib65","doi-asserted-by":"crossref","first-page":"A3764","DOI":"10.1182\/blood.V106.11.3764.3764","article-title":"Hematopoietic response to extended dosing of epoetin alfa 60,000 U every 2 weeks in anemic cancer patients not receiving therapy: final results","volume":"106","author":"Shasha","year":"2005","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.ejca.2006.10.014_bib66","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1200\/jco.2005.23.16_suppl.6621","article-title":"High-dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma","volume":"23","author":"Baz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib67","first-page":"1957","article-title":"Epoetin beta (NeoRecormon\u00ae) corrects anemia in patients with hormone refractory prostate cancer and bone metastases","volume":"24","author":"Bogdanos","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2006.10.014_bib68","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/S1359-6349(03)90613-6","article-title":"Treatment with epoetin beta corrects anemia and decreases transfusion use in patients with solid tumours or haematological malignancies","volume":"1","author":"Nowrousian","year":"2003","journal-title":"Eur J Cancer Suppl"},{"issue":"suppl 14","key":"10.1016\/j.ejca.2006.10.014_bib69","doi-asserted-by":"crossref","first-page":"8084","DOI":"10.1200\/jco.2004.22.90140.8084","article-title":"A controlled, randomized, open-label study to evaluate the effect of every 2-week darbepoetin alfa for anemia of cancer","volume":"22","author":"Charu","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib70","first-page":"197","article-title":"Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy","volume":"24","author":"Lalle","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.10.014_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3816\/CBC.2005.n.015","article-title":"Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life","volume":"6","author":"Hudis","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1634\/theoncologist.10-3-225","article-title":"Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial","volume":"10","author":"Reinhardt","year":"2005","journal-title":"Oncologist"},{"issue":"suppl 3","key":"10.1016\/j.ejca.2006.10.014_bib73","first-page":"A832P","article-title":"A randomised comparison of rHuEPO with darbepoetin for cancer related anemia","volume":"15","author":"Alexopoulous","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib74","doi-asserted-by":"crossref","first-page":"A5588","DOI":"10.1182\/blood.V106.11.5588.5588","article-title":"Use and outcomes of epoetin alfa and darbepoetin alfa for anemic cancer patients in outpatient community practice settings","volume":"106","author":"Fahrbach","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib75","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1359-6349(05)81638-6","article-title":"Breast-cancer anaemia and the value of erythropoietin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30,000 IU once weekly in patients with metastatic breast cancer receiving chemotherapy","volume":"3","author":"Marangolo","year":"2005","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2006.10.014_bib76","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib77","doi-asserted-by":"crossref","first-page":"A2915","DOI":"10.1182\/blood.V104.11.2915.2915","article-title":"Randomised, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy followed by surgery: Early termination of the trial due to increased incidence of throboembolic events","volume":"104","author":"Vadhan-Raj","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1634\/theoncologist.10-8-642","article-title":"Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 \u03bcg every 2 weeks) in anemic patients with cancer receiving chemotherapy","volume":"10","author":"Waltzman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2006.10.014_bib79","doi-asserted-by":"crossref","first-page":"A2261","DOI":"10.1182\/blood.V106.11.2261.2261","article-title":"Multiple cause of loss of recombinant erythropoietin efficacy: physicians beware","volume":"106","author":"Carson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2006.10.014_bib81","doi-asserted-by":"crossref","first-page":"A3149","DOI":"10.1182\/blood.V104.11.3149.3149","article-title":"Effect of epoetin beta on survival, tumour progression and thromboembolic events in patients with lymphoid malignancies receiving chemotherapy: a meta-analysis of controlled clinical studies","volume":"104","author":"Coiffier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.10.014_bib82","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00001813-199711000-00006","article-title":"A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy","volume":"8","author":"Pawlicki","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2006.10.014_bib83","article-title":"Saving costs in cancer anemia management. Recognizing functional iron deficiency (FID) and rationalizing EPO therapy","volume":"21","author":"Galliano","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.ejca.2006.10.014_bib84","first-page":"365","article-title":"Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non iron-depleted patients with lymphoproliferative disorders: results of the NIFe study","volume":"91","author":"Hedenus","year":"2006","journal-title":"Haematologica Haematol J"},{"issue":"suppl 18","key":"10.1016\/j.ejca.2006.10.014_bib85","first-page":"496s","article-title":"A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy","volume":"24","author":"Vandebroek","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib86","first-page":"1184","article-title":"Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy","volume":"14","author":"Aapro","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2006.10.014_bib87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/107327480301000606","article-title":"Anemia, cancer, and aging","volume":"10","author":"Balducci","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejca.2006.10.014_bib88","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1200\/JCO.2005.03.8570","article-title":"Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial","volume":"24","author":"Glaspy","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.10.014_bib89","first-page":"47","article-title":"Hepcidin \u2013 the iron regulatory hormone","volume":"26","author":"Rossi","year":"2005","journal-title":"Clin Biochem Rev"},{"issue":"suppl 8","key":"10.1016\/j.ejca.2006.10.014_bib90","first-page":"VIII37","article-title":"Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin","volume":"18","author":"Casadevall","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2006.10.014_bib91","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1023\/B:PHAM.0000008034.61317.02","article-title":"Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?","volume":"20","author":"Hermeling","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejca.2006.10.014_bib92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1185\/030079903125002702","article-title":"Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another","volume":"20","author":"MacDougall","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2006.10.014_bib93","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2141.2004.04861.x","article-title":"Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins","volume":"124","author":"Quint","year":"2004","journal-title":"Br J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906009609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906009609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:16:12Z","timestamp":1760732172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906009609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0959804906009609"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2006.10.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2006.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}